Interpharma’s Dr René P. Buholzer highlights the key lessons that Switzerland’s innovative pharmaceutical industry has taken from the COVID-19 pandemic, the challenges inherent in the country’s two upcoming cost containment packages, and progress made on the circuitous journey towards a more standardised national health data ecosystem.
Switzerland wants to have its cake and eat it – paying less for healthcare without seeing a drop in quality. We are a rich country that can afford high-quality healthcare and, while cost containment measures are understandable, they need to be implemented in a smart way, embracing new technologies without restricting innovation
